Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

BACKGROUND: This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC). METHODS: Eligible patients received sunitinib 37.5 mg/day and trastuzumab administered either weekly (loading, 4 mg/kg; then weekl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachelot, Thomas, Garcia-Saenz, Jose A, Verma, Sunil, Gutierrez, Maya, Pivot, Xavier, Kozloff, Mark F, Prady, Catherine, Huang, Xin, Khosravan, Reza, Wang, Zhixiao, Cesari, Rossano, Tassell, Vanessa, Kern, Kenneth A, Blay, Jean-Yves, Lluch, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995914/
https://www.ncbi.nlm.nih.gov/pubmed/24606768
http://dx.doi.org/10.1186/1471-2407-14-166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995914/
https://www.ncbi.nlm.nih.gov/pubmed/24606768
http://dx.doi.org/10.1186/1471-2407-14-166

Ejemplares similares